The Food and Drug Administration on March 10, 2026, approved leucovorin for an ultra-rare genetic disorder that can produce autism-like symptoms, while emphasizing that evidence remains limited for using the generic drug to treat autism spectrum disorder broadly. The move sharpened the contrast with the agency’s September 2025 messaging, when FDA Commissioner Marty Makary discussed changing leucovorin’s label in the context of helping some patients with autism symptoms. For families affected by autism, the distinction between a targeted genetic treatment and a general autism therapy is not academic; it determines whether a cheap, widely available generic drug has any proven role in care.
From September Optimism to March Restraint
The FDA’s reversal unfolded over roughly six months. In September 2025, the agency announced actions related to Wellcovorin, framing the move as an effort to make a treatment available for autism symptoms. An accompanying fact sheet from the Department of Health and Human Services reinforced that framing, though it also conceded that the evidence base for genetic cerebral folate deficiency consisted largely of small observational reports because the condition is extremely rare.
By March 2026, the agency had narrowed its position considerably. The FDA stated that evidence is not sufficient to support leucovorin use for autism broadly, restricting the formal approval to cerebral folate deficiency in patients with confirmed FOLR1 gene variants, a condition known as CFD-FOLR1. That approval relied on a systematic review of published literature, patient-level case reports, and mechanistic data rather than large clinical trials, according to the agency’s announcement.
The gap between those two positions matters. September’s announcement drew attention that some readers interpreted as a breakthrough for autism treatment. March’s clarification effectively confined the drug’s proven benefit to a tiny subset of patients with a specific, testable genetic mutation, leaving the broader autism population without new FDA-endorsed options.
What CFD-FOLR1 Actually Is
Cerebral folate transport deficiency caused by FOLR1 mutations is an ultra-rare neurological condition, not a subtype of autism. Patients with CFD-FOLR1 cannot properly transport folate into the brain, leading to developmental regression, seizures, movement disorders, and profound motor and cognitive delays. Some of these patients also display what clinical geneticists describe as autistic-like behaviors as part of a broader neurological picture. Treatment with leucovorin, also called folinic acid, can bypass the defective transport mechanism and deliver folate directly to the central nervous system.
Case-based evidence has shown neurological improvement in genetically confirmed CFD-FOLR1 patients treated with high-dose folinic acid. That evidence is real but narrow. The condition requires confirmed FOLR1 genetic variants for diagnosis, meaning it can be identified through specific testing and separated from idiopathic autism. The FDA’s approval of Wellcovorin for this indication makes clinical sense for this small group. The problem arises when that approval is interpreted, or presented, as validation for leucovorin use across the entire autism spectrum.
Two Small Trials and Their Limits
The scientific case for leucovorin in broader autism rests on two small, controlled studies, and neither provides the kind of evidence regulators typically require for a treatment indication. A randomized, double-blind, placebo-controlled trial published in Molecular Psychiatry tested high-dose folinic acid in children with autism and language impairment. That study reported gains in verbal communication, with the strongest responses seen in children who tested positive for folate receptor-alpha autoantibodies, known as FRAA. The finding suggested that a biomarker, FRAA status, might predict which children would benefit.
A second small trial, known as EFFET, evaluated folinic acid against placebo and found improvements in autism rating scores in the treatment group, with no serious adverse events reported. Both studies point in a promising direction and have fueled enthusiasm among some clinicians and parents. But both were small, and neither has been replicated at the scale that would typically support an FDA-approved indication for a condition as common and heterogeneous as autism.
This is the core tension the FDA now appears to be acknowledging. Preliminary trial results in selected subgroups are not the same as proof that a drug works for a broad diagnosis. The agency’s own materials indicated that FDA and NIH reviewed the evidence for autoimmune forms of cerebral folate deficiency, the mechanism linked to FRAA-positive patients, but stopped short of endorsing treatment based on that review alone. In effect, regulators are drawing a line between cautiously hopeful research and the much higher bar for a labeled indication.
The Political Backdrop
The FDA’s course correction did not happen in a vacuum. Commissioner Makary’s September 2025 remarks about changing leucovorin’s label came during a period of intense political interest in autism treatments and frustration over the slow pace of drug development. Reporting from Politico described the March announcement as the agency backing away from claims made by Robert F. Kennedy Jr. about the drug’s promise for autism patients.
That dynamic carries real consequences for patients and families. When senior officials suggest that an existing generic could help with autism symptoms, some parents may seek prescriptions from pediatricians and neurologists. If later clarifications emphasize that the evidence applies only to a very small genetic subgroup, it can complicate expectations and confidence in regulatory messaging. The March decision attempts to reset expectations, but it also underscores how quickly scientific nuance can be lost once a drug becomes entangled in political messaging.
What This Means for Families
For families of children with confirmed CFD-FOLR1, the FDA’s move is likely to be welcome news. An off-label, case-based practice now has formal regulatory backing, which may improve insurance coverage, standardize dosing, and encourage earlier diagnosis through targeted genetic testing. For these patients, leucovorin is no longer an experimental workaround but an approved therapy with a clear biological rationale.
For the far larger group of families navigating autism without a known FOLR1 mutation, the picture is more complicated. The March announcement effectively says that, at this point, leucovorin remains an experimental option whose benefits are unproven at the population level. Clinicians may still choose to prescribe it off-label, particularly for children who test positive for FRAA, but they will have to explain that the supporting data come from small trials and have not yet persuaded regulators to endorse a broad indication.
The decision also highlights the growing role of biomarkers in neurodevelopmental disorders. If future, larger trials confirm that FRAA-positive children with autism reliably benefit from folinic acid, leucovorin could eventually gain a narrower autism-related indication tied to antibody status rather than the entire spectrum. For now, however, that possibility remains hypothetical, and the FDA is signaling that it is not prepared to leap from suggestive subgroup findings to sweeping label changes.
Balancing Hope and Evidence
The leucovorin episode illustrates the challenge of balancing urgency with rigor in conditions like autism, where families are desperate for options and the therapeutic toolbox remains limited. Regulators are under pressure to show progress, especially when a potential treatment is inexpensive and already on the market. Yet lowering the evidentiary bar too far risks normalizing a standard in which promising signals are treated as proof, and reversals like the one between September and March become more common.
In stepping back from broad autism claims while approving leucovorin for CFD-FOLR1, the FDA is trying to thread that needle: endorsing a targeted, biologically coherent use of the drug while resisting the temptation to declare a breakthrough where the science is still emerging. For families and clinicians, the message is sobering but clarifying. Leucovorin is now a validated treatment for a specific, rare genetic disorder that can mimic some features of autism. It is not, at least yet, a proven therapy for autism itself.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
